Rachel E Johns

Title: Rachel E Johns: Innovator in Nucleic Acid Delivery

Introduction

Rachel E Johns is a prominent inventor based in Shoreline, WA (US). She has made significant contributions to the field of biotechnology, particularly in the development of lipopeptides for the delivery of nucleic acids. With a total of 2 patents, her work is paving the way for advancements in pharmaceutical compositions.

Latest Patents

Rachel's latest patents focus on lipopeptide compounds that facilitate the delivery of nucleic acid agents. One of her notable inventions includes lipopeptide compounds featuring a central peptide sequence HHHHHKHHHKKKHKHKKK (SEQ ID NO:15) with lipophilic groups attached to each terminus. These lipopeptides are designed for use in pharmaceutical compositions aimed at delivering nucleic acid agents, such as siRNA and mdRNA, and are instrumental in treating various diseases. Another patent details lipopeptide compounds with similar characteristics, emphasizing the versatility of the lipophilic groups, which can be derived from naturally occurring lipids or various alkyl and alkenyl structures.

Career Highlights

Rachel E Johns is currently associated with Marina Biotech, Inc., where she continues to innovate in the field of nucleic acid delivery systems. Her work is crucial in developing effective methods for delivering active agents to cells, including interfering-RNA agents and antisense RNAs.

Collaborations

Rachel collaborates with esteemed colleagues such as Roger C Adami and Michael E Houston, Jr. Their combined expertise enhances the research and development efforts at Marina Biotech, Inc.

Conclusion

Rachel E Johns is a trailblazer in the biotechnology sector, with her innovative patents significantly impacting the delivery of nucleic acids. Her contributions are vital for advancing therapeutic methods and improving patient outcomes.